Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Brain Sciences|July 27, 2024
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life StudyPiero Barbanti, Bianca Orlando, Gabriella Egeo, et al.
The Journal of Headache and Pain|December 13, 2023
Health equity, care access and quality in headache - part 2Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, et al.
Cephalalgia : an International Journal of Headache|June 6, 2025
Cortical thickness studies in migraine: Current evidence and future directionsBasit Ali Chaudhry, Samaira Younis, Roberta Messina, et al.
Mayo Clinic Proceedings|July 22, 2023
Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI StudyHåkan Ashina, David W Dodick, Jason Barber, et al.
Cephalalgia : an International Journal of Headache|February 2, 2026
Severity of physical, emotional, and cognitive symptoms is associated with future persistence of acute post-traumatic headache attributed to mild traumatic brain injuryLingchao Mao, Jing Li, Gina Dumkrieger, et al.
Cephalalgia : an International Journal of Headache|November 18, 2024
Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache SocietyFrancesca Puledda, Irene de Boer, Roberta Messina, et al.
Brain Communications|April 20, 2026
Traumatic brain injury recovery prediction by harmonizing real brain CT and synthetic brain MRI: a pilot studyYiming Che, Amogh Manoj Joshi, Jay Shah, et al.
Clinical Kidney Journal|October 4, 2021
Hypernatraemia and low eGFR at hospitalization in COVID-19 patients: a deadly combinationElisa Longhitano, Chiara Nardi, Vincenzo Calabrese, et al.
The Journal of Headache and Pain|July 24, 2021
Altered speech patterns in subjects with post-traumatic headache due to mild traumatic brain injuryCatherine D Chong, Jianwei Zhang, Jing Li, et al.
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Pageof 14